Glenmark Pharmaceuticals has introduced that its subsidiary Glenmark Specialty SA in Switzerland and an associate of Bausch Health Companies Inc. Have entered into an different licensing agreement for the commercialization of Glenmark’s progressive nasal spray RYALTRIS under assessment by Health Canada. Under the terms of the agreement, Glenmark may be answerable for regulatory approvals and deliver of RYALTRIS for the Canadian marketplace. Bausch Health, Canada could be accountable for the commercialization of RYALTRIS inside the Canadian marketplace, following regulatory approval. Glenmark will receive an in advance charge, launch & sales‐based totally milestone payments similarly to royalties and supply charge from income of RYALTRIS.